Trial Profile
A Multi-Centre, Randomized, Double-Blind, Five-Way Crossover Study Evaluating the Dose Response and Duration of Action of GSK2190915 Compared to Placebo in Subjects With Mild Asthma Who Experience Exercise Induced Bronchoconstriction.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Fiboflapon (Primary)
- Indications Exercise-induced asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Mar 2014 Primary endpoint 'Forced-expiratory-volume-in-1-second' has not been met.
- 01 Mar 2014 Results published in the Allergy and Asthma Proceedings.
- 08 Aug 2009 Actual number of patients (47) added as reported by ClinicalTrials.gov.